Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2017 3 549 M
EBIT 2017 1 126 M
Net income 2017 916 M
Debt 2017 1 687 M
Yield 2017 0,43%
Sales 2018 4 404 M
EBIT 2018 1 417 M
Net income 2018 1 177 M
Debt 2018 1 112 M
Yield 2018 0,49%
P/E ratio 2017 26,22
P/E ratio 2018 20,43
EV / Sales2017 7,25x
EV / Sales2018 5,71x
Capitalization 24 030 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
05/17 3SBIO : granted distribution right of insulin product in China
02/24 3SBIO : says 3 products listed in 2017 National Drug List
2016 3SBIO : granted exclusive license of diabetes drugs
2016 3SBIO : AstraZeneca Ink Licensing Agreement
2016 3SBIO : gets nod for colorectal cancer drug clinical trial
2016 3SBIO INC. : (01530) says ITP drug get clinical trial approval
2016DJChinese Drugmaker Plans up to $3 Billion Hong Kong IPO
2015 3SBIO : Selected as a Constituent of the Hang Seng Composite LargeCap & MidCap I..
2015 3SBIO : Acquires Zhejiang Wansheng Pharmaceutical
2015 3SBIO : Acquires Global Rights to Anti-TNF mAb
More news
Sector news : Biopharmaceuticals
03:18p Cross-border M&A between U.S. and European firms at 10 year high
08:32aDJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
06:58aDJAMGEN : Another Gloomy Day for Amgen
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
More sector news : Biopharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 10,4  CNY
Spread / Average Target 9,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu Chief Scientific Officer, President-R&D
Dong Mei Su Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)0.00%3 491
BIOGEN INC-4.30%53 048
CSL LIMITED30.52%44 146
ALEXION PHARMACEUTICAL..-6.96%25 564
GRIFOLS SA33.77%17 681
BIOMARIN PHARMACEUTICA..7.71%15 570
More Results